Shares of Ascendis Pharma ASND were flat in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share decreased 365.52% over the past year to ($2.70), which missed the estimate of ($1.86).
Revenue of $3,222,000,000 rose by 143546.90% year over year, which beat the estimate of $1,660,000.
Looking Ahead
Ascendis Pharma hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 11, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/bu6b6ks2
Recent Stock Performance
Company's 52-week high was at $178.25
52-week low: $92.00
Price action over last quarter: Up 14.98%
Company Description
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in the USA, Germany, and Switzerland and derives the majority of its revenue from the US.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
